Patent ID: 11859168
Assignee: CHRISTOPHER B. REID
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A method of cellular reprogramming for the interconversion of a differentiated or somatic cell of a first cell phenotype to at least one desired second, multipotent, pluripotent, self-renewing or differentiating phenotype, the method comprising:
transfecting a nucleated cell, wherein one or more transfection step is performed in vitro or in vivo, and wherein said nucleated cell is transfected with: a) a nucleic acid, b) a vector, c) a vector comprising synthetic oligonucleotides, d) a vector for gene therapy, e) a virus, f) a polypeptide, g) a ribonucleic acid or h) a deoxyribonucleic acid encoding a polypeptide, and wherein said polypeptide is;
i. one or more first polypeptide(s) selected from PRR+ Numb, Oct3/4, Sox2, Nanog and a polypeptide with LIF activity;
ii. one or more second polypeptide(s) selected from PRR+ Numb, Oct4, Sox2, Nanog, Notch, Fgf4, Hoxb4, Lin28, Lif, Lifr, Cntf, Cardiotrophin, Osm, Osm-r, Il6, Il6r, Hyper Il6, Il-11, Gp130, Stat3, C-myc, and a polypeptide with Lif Activity;
iii. one or more third polypeptide(s) selected from a short Numb isoform, Numblike, MyoD, myogenin, Myocardin, Ifrdl, Myf 5, Myf 6, Mef2, Gata 4, Gata 5, Gata 6, Sox9, CREB-binding polypeptide, Runx2, HNF-1, HNF-3, HNF-4, HNF-6, Nurr1, REN, Neurogenin1, Neurogenin2, Neurogenin3, Mash1, Phox2a, Phox2b, dHand, Gata3, Shh, FGF8, Lmx1b, Nkx2.2, Pet1, Lbx1, Rnx, PITX2, D1x2, D1x5, Ngn2, Ptx3, Gata2, REST4, Foxa2, Sox17, HLXB9, Runx1/AML, Pdxl, OLIGI, OLIG2, NOV(CCN3), and Zfp488; and/or
iv. one or more fourth polypeptide(s) altering the amount, activity or antigenicity of a cellular protein.